title: Protease-Activated Receptor-1 Antagonists Post-Percutaneous Coronary Intervention.
abstract: Thrombin is a potent platelet agonist, and protease-activated receptor-1 (PAR-1) is the main thrombin receptor in human platelets and thrombin. PAR-1 antagonism has attracted interest as a potential therapeutic target to reduce atherothrombotic events in patients with atherosclerotic disease, especially coronary artery disease. In this review, the author describes the rationale of PAR-1 antagonism for the reduction of atherothrombotic events and reviews the key phase 3 trial results, with special attention to analyses in percutaneous coronary intervention patients.
authors.affiliation: Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, 0311 Terrace Level, Box 3850 DUMC, Durham, NC 27705, USA. Electronic address: pierluigi.tricoci@duke.edu.
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Tricoci
mesh_terms: D003324:Coronary Artery Disease / Q000601:surgery*; D006801:Humans; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000097:blood / Q000517:prevention & control*
chemical_list: D010975:Platelet Aggregation Inhibitors
keywords: Antiplatelet therapy; Coronary artery disease; Myocardial infarction; Percutaneous coronary intervention; Protease-activated receptors; Vorapaxar